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Abstract  23 
Aims: To examine the association between late pregnancy exposure to serotonin reuptake 24 
inhibitor (SRI) antidepressants and difficulties in achieving an adequate breast milk supply in 25 
women who gave birth to preterm infants, while accounting for the potential impacts of 26 
underlying maternal psychiatric illness. 27 
Methods: Retrospective cohort study of 3,024 women delivering liveborn preterm infants 28 
(<37 weeks’ gestation) between January 2004 and December 2008. The primary outcome 29 
was postnatal domperidone use, considered a valid proxy for presence and pharmacological 30 
management of low milk supply. Relative risks adjusted for maternal soiodemographics and 31 
comorbidities (aRRs) were calculated for low milk supply, comparing women with late 32 
pregnancy exposure to SRI antidepressants (n = 86), women with a psychiatric illness but no 33 
antidepressant use (n = 126), and women with neither antenatal exposures (n = 2 812).  34 
Results: Compared to non-exposed women, non-medicated psychiatric illness (aRR 1.64; 35 
95%CI 1.16-2.30) but not late pregnancy SRI use (aRR 1.00; 95%CI 0.59-1.70) was 36 
associated with an increased risk of domperidone use, indicative of low milk supply.  37 
Conclusions: These findings do not support the previously observed negative impacts of 38 
antidepressant use on breastfeeding, instead suggesting that women with an underlying 39 
psychiatric illness appear at greatest risk of experiencing low milk supply and could benefit 40 
from additional breastfeeding education and support. 41 
Keywords: serotonin agents, antidepressive agents, breastfeeding, lactation, premature birth 42 
 43 
Structured Summary 44 
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Statement 1: What is already known about this subject 45 
• Serotonin plays an important role in human breast milk volume homeostasis within 46 
the mammary gland during lactation 47 
• Previous research demonstrates women taking antidepressants have lower rates of 48 
breastfeeding intention and initiation and are more likely to experience delayed 49 
secretory activation 50 
• Whether use of SRIs during lactation is associated with a reduction in breast milk 51 
volume or leads to impaired long-term breastfeeding outcomes is unclear 52 
 53 
Statement 2: What this study adds 54 
• In a cohort of mothers of preterm infants, use of SRIs in late pregnancy was not 55 
associated with an increased risk of experiencing low milk supply  56 
• Women with an underlying psychiatric illness appear at greatest risk of experiencing 57 
low milk supply and could therefore benefit from additional breastfeeding education 58 
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Main Body of Text 63 
Introduction:  64 
Serotonin has been identified as playing an important role in human breast milk volume 65 
homeostasis within the mammary gland during lactation, with increased levels leading to 66 
mammary gland involution and reduced milk production.1 This raises concerns that 67 
medications that alter serotonin signaling, such as the serotonin reuptake inhibitor (SRI) 68 
antidepressants, may interfere with the normal physiological processes involved in lactation 69 
and therefore place women at increased risk of poor breastfeeding outcomes. Previous 70 
research has identified that women taking antidepressants have lower rates of breastfeeding 71 
intention and initiation,2, 3 but most recent evidence suggests this is largely due to residual 72 
confounding from underlying maternal psychiatric illness.4 Marshall et al, however, 73 
demonstrated an association between maternal Selective Serotonin Reuptake Inhibitor (SSRI) 74 
use and delayed secretory activation (defined as onset of copious milk production; also 75 
known as stage II lactogenesis) which was independent of underlying maternal depressive 76 
illness.5 While it is well established that delayed secretory activation is associated with a 77 
reduced duration of breastfeeding,6 whether this observed delay associated with SSRI use is 78 
also associated with a reduction in breast milk volume or leads to impaired long-term 79 
breastfeeding outcomes is unclear. Therefore, the aim of this study was to examine the 80 
association between late pregnancy exposure to SRIs and difficulties in achieving an 81 
adequate breast milk supply in women who gave birth to preterm infants, while accounting 82 
for the potential impacts of underlying maternal psychiatric illness.  83 
 84 
Methods:  85 
Ethical Approval 86 
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This project was approved by the Women’s and Children’s Health Network Human 87 
Research Ethics Committee (REC2219-10-14).  88 
 89 
Study Design and Setting 90 
We conducted a retrospective cohort study of all women delivering liveborn preterm 91 
infants (<37 weeks’ gestation) at the Women’s and Children’s Hospital (WCH) in South 92 
Australia between January 2004 and December 2008 (n=3 054). We excluded women exposed 93 
to antidepressants other than serotonin reuptake inhibitors (n=13) or antipsychotics (n=17), 94 
leaving a final cohort of 3 024 women. 95 
The WCH is accredited as part of the Baby Friendly Hospital Initiative (BFHI) and has 96 
a dedicated lactation support service. This study utilised linkable electronic health 97 
administrative data within the WCH, including the WCH Perinatal Statistics Collection and the 98 
WCH Hospital Pharmacy Dispensing Records. The Perinatal Statistics Collection (PSC) 99 
includes electronic data on the pregnancy and outcome of every live birth and late fetal death 100 
occurring at the hospital.7 The information in the PSC has been previously validated and is 101 
reliable when compared with hospital case records.8 These data have been previously utilised 102 
to investigate outcomes associated with the use of antidepressants during pregnancy and the 103 
use of domperidone for the management of low milk supply, the full details of which have been 104 
previously published elsewhere.9, 10  105 
 106 
Measures 107 
Antidepressant use and psychiatric illness 108 
Late pregnancy exposure to serotonin reuptake inhibitors was identified from the WCH 109 
Pharmacy Dispensing Records. Women were classified as exposed if they were dispensed a 110 
serotonin reuptake inhibitor antidepressant during late pregnancy (second and third trimesters). 111 
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Hospital pharmacy dispensing records have previously been validated as an indicator of 112 
exposure to antidepressants in late pregnancy, including exposure around the time of delivery.7. 113 
In an effort to obtain a suitable comparison group consisting of women with similar underlying 114 
disease to those exposed to antidepressants during pregnancy, we identified a cohort of women 115 
with an identified psychiatric illness during pregnancy but who were not dispensed an 116 
antidepressant (disease comparison termed ‘nonmedicated psychiatric illness’). The presence 117 
of a psychiatric illness during pregnancy was identified from the electronic PSC, with 118 
midwives recording the diagnosis if the woman is receiving medication for her psychiatric 119 
illness or if it was recorded in the notes that the woman received psychological/psychiatric 120 
support during her pregnancy. This has been utilised as a disease comparator group in previous 121 
studies.11 The remaining group of women consisted of those who did not have a psychiatric 122 
illness and were not dispensed an antidepressant (termed ‘non-exposed’). 123 
 124 
Breastfeeding Outcomes and Domperidone use 125 
The primary outcome was postnatal domperidone use. Domperidone is a galactagogue 126 
which stimulates and promotes milk production and is commonly used as a pharmacological 127 
treatment for mothers who are experiencing lactation difficulties.12, 13 Therefore, domperidone 128 
use was considered a proxy for the presence and pharmacological management of low milk 129 
supply. Data relating to women dispensed domperidone were obtained from the WCH 130 
Pharmacy Dispensing Records in accordance with previously published methods.14 131 
Domperidone is only able to be prescribed by medical doctors for mothers of preterm infants 132 
in the neonatal unit utilising a pre-printed prescribing checklist, with no restrictions according 133 
to level of experience (e.g. interns, registrars and consultants all eligible to prescribe). 134 
Prescribers in the Neonatal Unit are only allowed to prescribe mother’s domperidone for the 135 
explicit indication of lactation insufficiency, with mothers referred to other physicians for the 136 
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management of conditions not affecting their infant. Further, we have previously undertaken a 137 
detailed medication chart review for a random selection of 215 of 1,605 mother-infant dyads 138 
where domperidone was prescribed, with 100% of records indicating that domperidone was 139 
prescribed for lactation insufficiency.9 Guidelines regarding the use of domperidone or 140 
management of low milk supply during this time period have remained consistent, 141 
recommending domperidone as the first-line pharmacological treatment. Domperidone is the 142 
most widely prescribed first-line agent for management of maternal low milk supply across 143 
Australian neonatal units.13 Data on any breastfeeding at neonate discharge from hospital are 144 
routinely collected and were utilised to determine additional breastfeeding outcomes. 145 
Furthermore, in the 2008 calendar year only, additional data were also available pertaining to 146 
initiation of breastfeeding and exclusivity of breastfeeding during infant admission to the 147 
Neonatal Unit.  148 
 149 
Covariates  150 
Data on additional maternal and neonatal characteristics were obtained from the PSC. 151 
Maternal age and body mass index (BMI) was determined at the time of first antenatal 152 
booking visit. Women were classified as non-smokers or smokers during pregnancy based on 153 
maternal self-report at the first antenatal visit. The estimated length of gestational age at 154 
delivery is based on the last menstrual period and ultrasound examination. According to 155 
parity, women were classified as either primiparous or multiparous. Method of delivery was 156 
classified as either vaginal delivery (including instrumental deliveries) or lower segment 157 
caesarean section (LSCS; including elective and emergency). Maternal ethnicity was 158 
classified as Caucasian or other. Socioeconomic status for each woman was determined using 159 
her residential postcode at the time of delivery. Women were then ranked according to their 160 
level of advantage or relative disadvantage, based on data from the Socio-Economic Indexes 161 
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for Areas (SEIFA), calculated from the Australian Bureau of Statistics’ (ABS) five-yearly 162 
Census of Population and Housing. SEIFA scores were converted to quintiles, representing 163 
widely used measures of relative socio-economic status.  164 
 165 
Data Analyses 166 
The association between maternal SRI exposure status and domperidone use was 167 
evaluated using a generalised linear model (Poisson distribution) with robust variance 168 
estimates (and resulting relative risks (RR) and 95% confidence intervals). Analyses were 169 
adjusted for possible confounders including maternal age, parity, smoking status, 170 
socioeconomic status, and gestational age at birth. We also conducted a sensitivity analysis 171 
restricting the analysis to the 2008 calendar year when data on breastfeeding initiation and EBF 172 
at discharge were available. Statistical significance was defined as a two-sided p-value of 173 




Among the cohort of 3024 eligible women, 86 (2.8%) were exposed to a SRI in late 178 
pregnancy, 126 (4.2%) were exposed to non-medicated psychiatric illness and the remaining 179 
2812 (93.0%) were non-exposed.  180 
Table 1 describes the demographic and clinical characteristics of women according to 181 
exposure status. While women exposed to SRIs in late pregnancy differed from non-exposed 182 
women across a number of characteristics, they were largely representative of women with 183 
non-medicated psychiatric illness. 184 
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The prevalence of domperidone use was highest among women with non-medicated 185 
psychiatric illness (23.8%), followed by those with SRI use (16.3%) and those who were non-186 
exposed (14.6%). The unadjusted and adjusted differences in domperidone use between 187 
groups are presented in Table 2. Compared to non-exposed women, non-medicated 188 
psychiatric illness (aRR 1.64; 95%CI 1.16-2.30) but not late pregnancy SRI use (aRR 1.00; 189 
95%CI 0.59-1.70) was associated with an increased use of domperidone use, indicative of 190 
low milk supply. 191 
The cumulative percentage of women dispensed domperidone postpartum according 192 
to late pregnancy exposure status is presented in Figure 1. Across all groups more than 50% 193 
of women who received domperidone were dispensed it within the first 3 weeks postpartum. 194 
The rate of domperidone use appeared similar among the SRI use and non-medicated 195 
psychiatric illness groups within the first 3 weeks postpartum, before tapering off in the SRI 196 
use group while continuing to increase in the non-medicated psychiatric illness group. Figure 197 
2 demonstrates that the prevalence of domperidone use was highest among mother’s with a 198 
non-medicated psychiatric illness across all gestations.  199 
In a sensitivity analysis involving only those women who delivered in the 2008 200 
calendar year where data were available on breastfeeding initiation and we were able to 201 
restrict the cohort to women who initiated breastfeeding, no difference in domperidone use 202 
was observed between women with SRI use in late pregnancy and non-medicated psychiatric 203 
illness (RR 1.05; 95%CI 0.28-3.94). When further restricted to primiparous women, no 204 
difference in domperidone use was observed between women with SRI use in late pregnancy 205 
and non-medicated psychiatric illness (RR 1.06; 95%CI 0.49-2.28). 206 
Discussion 207 
Main Findings 208 
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We found that use of SRIs in late pregnancy is not associated with an increased risk of 209 
domperidone use in mothers of preterm infants. These findings suggest that use of serotonin 210 
disrupting antidepressants during lactation do not appear to place women at increased risk of 211 
experiencing low milk supply.  212 
 213 
Strengths and Limitations 214 
To our knowledge, this is the largest study undertaken to investigate the potential 215 
impacts of maternal SRI use and non-medicated psychiatric illness on breast milk supply 216 
difficulties. The major strength of this study lies in the identification of a group of women 217 
with non-medicated psychiatric illness to provide greater adjustment for potential 218 
confounding associated with underlying maternal illness. Further, utilisation of data on 219 
domperidone use as a proxy for the presence of low milk supply represents a novel approach 220 
towards addressing a topic of particular significant importance, with a previous clinical audit  221 
finding 100% agreement between domperidone use and management of lactation 222 
insufficiency. In accordance with hospital policy, domperidone is supplied to mothers in the 223 
Neonatal Unit utilising a carefully developed prescribing checklist which requires prescriber 224 
acknowledgement of persistent low milk supply despite previous utilisation of non-225 
pharmacological interventions. Therefore, domperidone supply is likely to represent those 226 
women experiencing the greatest breastfeeding difficulties. Further strengths of this study 227 
include undertaking additional sensitivity analyses to determine the potential impact of 228 
breastfeeding initiation on observed breastfeeding outcomes. 229 
There are a number of limitations associated with this study. Use of hospital 230 
pharmacy dispensing data may not have identified all women who were taking an 231 
antidepressant in late pregnancy, meaning some women in the control groups may have been 232 
exposed to SRIs unknowingly. Such misclassification, however, is likely to be non-233 
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differential with respect to the outcome under investigation and therefore is unlikely to have 234 
impacted greatly on the effect estimate.15 We are not able to confirm that women exposed to 235 
a SRI in late pregnancy continued to take it while breastfeeding and we do not have data on 236 
whether women in the non-medicated psychiatric illness or non-exposed group were 237 
prescribed an antidepressant in the postpartum period. However, based on previous drug 238 
utilisation studies,16 the number of women in the non-medicated psychiatric illness group 239 
who may have been previously on an antidepressant and then restarted it during lactation is 240 
likely to be low, as is the relative number of women in the non-exposed group who may have 241 
been newly prescribed an antidepressant in the postpartum period. In addition, there was no 242 
measure of the type and severity of maternal psychiatric illness, which would have added to 243 
understanding the independent effects of psychiatric illness on the risk of low milk supply, 244 
and we did not assess the impact of dose or indication of SRI use. A noted limitation is that 245 
women identified as having a non-medicated psychiatric illness (which excluded users of 246 
non-SSRI antidepressant or antipsychotics) reflect a heterogenous group with a range of 247 
likely psychiatric diagnoses and severities reflecting imbalances of other neurotransmitters, 248 
besides serotonin. Lastly, given we restricted the study to mothers of preterm infants. It is 249 
unclear whether the findings will also be generalizable to mothers of term infants.  250 
 251 
Interpretation 252 
The role of serotonin and serotonin transport in the regulation of lactation has been 253 
reviewed in detail elsewhere.17 In brief, numerous animal studies have established 254 
serotonergic transmission as a key regulator of lactation homeostasis, with increased levels of 255 
serotonergic activity (including through use of SRIs) accelerating the rate of mammary gland 256 
involution, leading to a reduction in milk production.17  Whether similar effects occur in 257 
humans is unclear, with it previously noted that the mammary glands of mice, cattle and 258 
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humans express unique patterns of 5-HT receptors that vary among the species.18 The 259 
potential impacts of SRI exposure have only been investigated in one human study, where 260 
maternal SSRI use was associated with a 2-fold delay in secretory activation.5. In comparison 261 
to our study, there are a few note-worthy differences that could explain inconsistent study 262 
findings. The findings from Marshall et al. were based on a total of only 8 mothers of term 263 
infants exposed to SSRIs, compared to our sample of 86 women taking SRIs. Furthermore, 264 
all women had experienced secretory activation by day 7, with no examination of breast milk 265 
volume or longer term breastfeeding outcomes.5 We focused on mothers of preterm infants as 266 
this was envisaged to enable us to obtain more complete data on domperidone use occurring 267 
within the hospital and the longer neonatal hospital admission enabled examination of longer 268 
term breastfeeding outcomes. Further, mothers of preterm infants are the most vulnerable for 269 
experiencing difficulties with milk supply and their infants benefit the most from the 270 
available of mother’s own milk for feeding. Given the additional breastfeeding supports often 271 
available to mothers of preterm infants, it is possible that these may overcome any challenges 272 
related to delayed secretory activation and therefore avoid potential negative impacts posed 273 
by serotonin disruption during lactation. 274 
Notably, these findings do not provide evidence against a role of serotonin in 275 
lactation, rather, they provide evidence that interference of serotonin signalling through 276 
antidepressant use is unlikely to directly impact on breast milk production. It is well 277 
recognised that successful lactation is moderated by a range of behavioural, social, clinical, 278 
and biological factors, with one of the most significant clinical factors being giving birth to a 279 
preterm infant.19 Of note, previous studies have demonstrated that acute and chronic physical 280 
and mental stress can impair the milk ejection reflex by attenuating oxytocin release.19 This 281 
could lead to incomplete emptying of the breast and a resultant reduction in overall milk 282 
production. This may explain why underlying maternal psychiatric illness appeared to have 283 
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the greatest impact on inadequate breast milk supply and point towards the needs for 284 
increased awareness of maternal illnesses that can impact on milk supply to identify women 285 
that may require additional support and education to attain optimal breastfeeding outcomes. 286 
These findings suggest the need to provide additional attention and support to women taking 287 
antidepressants during lactation. Although the risks to the breastfed infant associated with 288 
antidepressant use in lactation are considered low, the choice to breastfeed when taking an 289 
antidepressant may pose a dilemma for some women.20 Concerns regarding infant “exposure” 290 
through human milk may lead to unnecessary anxiety among mothers and in turn negatively 291 
impact on the physiological processes involved in lactation or their determination to persist 292 
with any breastfeeding difficulties should they arise.  293 
In conclusion, we found no evidence that use of SRIs in late pregnancy was 294 
associated with an increased risk of low milk supply in mothers of preterm infants. Women 295 
with an underlying psychiatric illness appear at greatest risk of experiencing low milk supply 296 
and could therefore benefit from additional breastfeeding education and support. 297 
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Table 1. Demographic and Clinical Characteristics for Mothers of Preterm Infants 
Exposed to Serotonin Reuptake Inhibitors, Non-Medicated Psychiatric Illness, or 











Age, mean ± SD 30.2 (5.3) 29.0 (6.2) 29.5 (6.2) 
Maternal BMI (kg/m2), mean ± 
SD 
26.9 (6.1) 26.6 (6.8) 26.3 (6.6) 
Parity    
Multiparous, n(%)† 50 (58.1) 71 (56.4) 1 441 (51.4) 
Smoking status, n(%)†    
Non-smoker 52 (61.9) 68 (56.7) 1 889 (74.2) 
Quit during pregnancy 2 (2.4) 7 (5.8) 95 (3.7) 
Smoker 30 (35.7) 45 (37.5) 562 (22.1) 
Ethnicity, n (%)†    
Caucasian 82 (95.4) 116 (92.1) 2 289 (81.4) 
Other 4 (4.7) 10 (7.9) 523 (18.6) 
Socioeconomic status, SEIFA, 
n(%)† 
   
5 (Highest) 11 (12.8) 21 (16.7) 441 (15.8) 
4 10 (11.6) 25 (19.8) 483 (17.3) 
3 15 (17.4) 19 (15.1) 478 (17.1) 




  377 
2 16 (18.6) 21 (16.7) 665 (23.8) 
1 (Lowest) 34 (39.5) 40 (31.8) 732 (26.2) 
Psychotropic medication use, 
n(%)† 
6 (7.0) 10 (7.9) 50 (1.8) 
Substance abuse, n(%)† 6 (7.0) 19 (15.1) 144 (5.1) 
Delivery type    
Caesarean section 50 (58.1) 67 (53.2) 1 424 (50.6) 
Gestational age (Weeks), median 
(Range) 
35 (25-36) 34 (22-36) 34 (23-36) 
Dispensed domperidone, n(%)† 14 (16.3) 30 (23.8) 410 (14.6) 
Initiated breastfeeding‡, n(%)† 19 (95.0) 12 (85.7) 499 (88.3) 
Any breastfeeding at neonatal 
discharge from hospital, n(%)† 
74 (86.1) 105 (84.0) 2 379 (84.8) 
2008 cohort only (n=305)    
Exclusively breastfeed infant 
during entire neonatal unit 
admission ‡, n(%)† 
4 (20.0) 1 (7.1) 115 (20.4) 
† Percentages are calculated from non-missing data 






Table 2. Multivariate Analysis of Postnatal Domperidone Use According to Maternal 
Psychiatric Illness and Prenatal SRI Exposure During Late Pregnancy 
SRI Use Vs.  
Non-Exposed 




Illness Vs. Non-Exposed 
Unadjusted RR (95% CI) 
1.12 (0.66, 1.87) 0.68 (0.37, 1.25) 1.63 (1.17, 2.28) 
Adjusted RR (95% CI)a 
1.00 (0.59, 1.70) 0.62 (0.33, 1.16) 1.64 (1.16, 2.30) 
Abbreviations: SRI, serotonin reuptake inhibitor; aRR, adjusted relative risk; CI, 
confidence interval 
a RR adjusted for maternal age, parity, smoking status, socioeconomic status, and 
gestational age at birth 
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Figure Captions: 381 
Figure 1: Cumulative Percentage of Women Dispensed Domperidone Postpartum According 382 
to Late Pregnancy Exposure Status 383 
 384 
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Figure 2: Percentage of Women Prescribed Domperidone According to Exposure Status and 386 
Gestational Age at Birth 387 
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